Lista de obras - Björn Tackenberg - Dominio Público Uruguay

Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial).

artículo científico publicado en 2018

Afferent Visual Pathway Affection in Patients with PMP22 Deletion-Related Hereditary Neuropathy with Liability to Pressure Palsies.

artículo científico publicado en 2016

Akinetic crisis caused by rectus sheath hematoma and acute anemia due to subcutaneous administration of apomorphine

artículo científico publicado en 2006

Anti-JC-virus antibody prevalence in a German MS cohort

artículo científico publicado en 2012

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis

scientific article published on 01 July 2019

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

artículo científico publicado en 2018

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.

artículo científico publicado en 2017

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society

artículo científico publicado en 2016

Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study

artículo científico publicado en 2020

Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis

scientific article published on 05 May 2020

Cytokines and epilepsy

artículo científico publicado en 2011

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.

artículo científico publicado en 2018

Deregulated Fcγ receptor expression in patients with CIDP.

artículo científico publicado en 2015

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab

artículo científico publicado en 2016

EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2

artículo científico publicado en 2008

Economic burden in a German cohort of patients with multiple sclerosis

artículo científico publicado en 2011

Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).

artículo científico publicado en 2013

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation

scientific article published on 16 November 2018

Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data

artículo científico publicado en 2020

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

artículo científico publicado en 2012

Genetic determinants of the humoral immune response in MS

artículo científico publicado en 2020

Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)

artículo científico publicado en 2020

Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy

artículo científico publicado en 2010

IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis

scientific article published on 16 December 2019

IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis

artículo científico publicado en 2012

Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis

artículo científico publicado en 2011

Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy

scholarly article

Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE).

artículo científico publicado en 2018

Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus

artículo científico publicado en 2016

Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis.

artículo científico publicado en 2011

Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation

artículo científico publicado en 2014

Is APOE ε4 associated with cognitive performance in early MS?

scientific article published on 01 May 2020

Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab

scientific article published on 13 December 2019

Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study

scientific article published on 01 April 2020

Low frequency and rare coding variation contributes to multiple sclerosis risk

MK2 and Fas receptor contribute to the severity of CNS demyelination

artículo científico publicado en 2014

Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease

artículo científico publicado en 2015

Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.

artículo científico publicado en 2010

Myasthenia gravis: analysis of serum autoantibody reactivities to 1827 potential human autoantigens by protein macroarrays

artículo científico publicado en 2013

NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy

artículo científico publicado en 2008

Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients

artículo científico publicado en 2013

Neurofascin as a target for autoantibodies in peripheral neuropathies

artículo científico publicado en 2012

Nigrostriatal dysfunction in X-linked dystonia-parkinsonism (DYT3).

artículo científico publicado en 2007

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation

artículo científico publicado en 2016

Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany

scientific article published on 12 August 2020

PML risk stratification using anti-JCV antibody index and L-selectin.

artículo científico publicado en 2015

Potassium channel KIR4.1 as an immune target in multiple sclerosis

artículo científico publicado en 2012

Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod

artículo científico publicado en 2014

Preference-based Health status in a German outpatient cohort with multiple sclerosis

artículo científico publicado en 2013

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany

article

Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08

scientific journal article

Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood

artículo científico publicado en 2017

Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity

artículo científico publicado en 2015

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array

artículo científico publicado en 2015

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

artículo científico publicado en 2021

Survey of diagnostic and treatment practices for multiple sclerosis in Europe, part 2: progressive MS, paediatric MS, pregnancy and general management

artículo científico publicado en 2018

Terminal complement activation is increased and associated with disease severity in CIDP

artículo científico publicado en 2016

The immunopathogenesis of myasthenia gravis

artículo científico publicado en 2008

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

artículo científico publicado en 2018

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.

artículo científico publicado en 2017

Whole-body vibration therapy in intensive care patients: A feasibility and safety study

artículo científico publicado en 2016

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany]

scientific article published on 01 December 2019

Lista de obras de Björn Tackenberg

Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial).

Afferent Visual Pathway Affection in Patients with PMP22 Deletion-Related Hereditary Neuropathy with Liability to Pressure Palsies.

Akinetic crisis caused by rectus sheath hematoma and acute anemia due to subcutaneous administration of apomorphine

Anti-JC-virus antibody prevalence in a German MS cohort

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society

Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study

Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis

Cytokines and epilepsy

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.

Deregulated Fcγ receptor expression in patients with CIDP.

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab

EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2

Economic burden in a German cohort of patients with multiple sclerosis

Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation

Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

Genetic determinants of the humoral immune response in MS

Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)

Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy

IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis

IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis

Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis

Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy

Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE).

Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus

Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis.

Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation

Is APOE ε4 associated with cognitive performance in early MS?

Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab

Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study

Low frequency and rare coding variation contributes to multiple sclerosis risk

MK2 and Fas receptor contribute to the severity of CNS demyelination

Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease

Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.

Myasthenia gravis: analysis of serum autoantibody reactivities to 1827 potential human autoantigens by protein macroarrays

NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy

Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients

Neurofascin as a target for autoantibodies in peripheral neuropathies

Nigrostriatal dysfunction in X-linked dystonia-parkinsonism (DYT3).

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation

Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany

PML risk stratification using anti-JCV antibody index and L-selectin.

Potassium channel KIR4.1 as an immune target in multiple sclerosis

Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod

Preference-based Health status in a German outpatient cohort with multiple sclerosis

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany

Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08

Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood

Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

Survey of diagnostic and treatment practices for multiple sclerosis in Europe, part 2: progressive MS, paediatric MS, pregnancy and general management

Terminal complement activation is increased and associated with disease severity in CIDP

The immunopathogenesis of myasthenia gravis

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.

Whole-body vibration therapy in intensive care patients: A feasibility and safety study

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany]